Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CMC Biologics has entered into an agreement with RuiYi for the development of a novel anti-IL-6 monoclonal antibody.
Subscribe to our email newsletter
The CMC’s CHEF1 high-productivity expression plasmid will be leveraged for the cell line development to optimize cell growth, and consistent, high-level protein expression in a rapid time frame.
Terms of the deal have not been revealed.
RuiYi president and CEO Paul Grayson said, "The integrated services, including cell line development using the proprietary CHEF1 system, along with CMC’s responsive and collaborative interactive style made CMC Biologics the obvious partner for this important global effort."
CMC Biologics business development global vice president Mark Sawicki said, "RYI-008 is an antibody with unprecedented potency and remarkable half-life, creating a significant opportunity to be a best in class product in the rapidly evolving field of IL-6 biology."